Skip Navigation

Your Environment. Your Health.

Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage

Open for Recruitment

Study Background

Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage

Open for Recruitment

The gene p53 suppresses cancer and inflammation in the body, and NIEHS investigators speculate that changes in p53 lead to changes in inflammation and the ability to repair DNA damage. This study wants blood samples from participants to find out how the changes in p53 lead to these conditions.

Research has shown that certain proteins in cells may be linked to higher risk of developing inflammation, tumors, and other medical problems. By examining how the blood cells of healthy volunteers respond to environmental exposures, researchers hope to better understand the relationship of genes, environmental factors, and human diseases.

For more information on this study, please visit the Clinical Trials Study page.

This content is available to use on your website.
Please visit NIEHS Syndication to get started.

Eligibility

  • Current participant in the Environmental Polymorphism Registry (EPR)
  • Ages Eligible for Study: 18 Years and older
  • Genders Eligible for Study: Both
  • Accepts Healthy Volunteers: Yes

Inclusion Criteria:

  1. Male or female 18 years of age or older
  2. Participants must be able to understand and provide written informed consent to participate in the study 
  3. Participants must be able to travel to the CRU 
  4. Healthy participants as defined by the International Red Cross guidelines (Healthy means that an individual feels well and can perform normal activities. If the individual has a chronic condition such as diabetes or high blood pressure, healthy also means that they are being treated and the condition is under control). 

Exclusion Criteria: 

  1. Use of immunosuppressants or other immune-modifying drugs [e.g., Rituxan, Humira, Enbrel, Cyclosporin (Neoral, Sandimmune, and SangCya), Azathioprine (Imuran)], Monoclonal antibodies [e.g., infliximab (Remicade)], Corticosteroids (e.g., prednisone, prednisolone and dexamethasone)
  2. History of being treated for cancer by chemotherapy or radiation 
  3. Confirmed or suspected immunosuppressive or immunodeficient condition 
  4. Body weight < 50 kg (< 110 lbs) 
  5. Temperature > 37.6 C; blood pressure < 90/50 mm Hg or blood pressure > 170/95 mm Hg; pulse rate < 50 or > 100 beats/minute 
  6. Participants carrying SNPs TLR8 and FLT1 who are currently taking hormonal contraception (e.g. oral contraceptives, IUDs with hormones, contraceptive patches) or hormone replacement therapy will be excluded from the study unless the participant has been off of the hormone treatment for 1 month or longer.

What will you do?

  • The study will involve one visit of 45 to 60 minutes. 
  • Participants will be screened with a brief physical examination and finger stick to determine if they are eligible to donate blood for the study, and will complete a questionnaire about any medications or other drugs (e.g., cigarettes) they may be taking.
  • Participants will provide a blood sample for research purposes.

Study Location

Sample collections are conducted at the NIEHS Clinical Research Unit located in Research Triangle Park, North Carolina.

Protocol Number: 10-E-0134

Enrollment and Contact Information

To volunteer or learn more, contact Grace Isshiki at (919) 541-4973.

Principal Investigator

Daniel Menendez, Ph.D.
Daniel Menendez Rendon, Ph.D.
Staff Scientist
Tel 919-541-0972
Fax 919-541-7593
menendez@niehs.nih.gov
P.O. Box 12233
Mail Drop D3-01
Durham, N.C. 27709